MedPath

Athenex, Inc.

Athenex, Inc. logo
🇺🇸United States
Ownership
Private
Established
2003-01-01
Employees
280
Market Cap
-
Website
http://www.athenex.com

Clinical Trials

27

Active:2
Completed:16

Trial Phases

3 Phases

Phase 1:23
Phase 2:3
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials

Phase 1
23 (85.2%)
Phase 2
3 (11.1%)
Phase 3
1 (3.7%)

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

Phase 1
Recruiting
Conditions
B-cell Leukemia
DLBCL - Diffuse Large B Cell Lymphoma
ALL, Childhood
NHL, Relapsed, Adult
B-cell Lymphoma
ALL, Adult B Cell
CLL/SLL
First Posted Date
2022-08-04
Last Posted Date
2023-05-18
Lead Sponsor
Athenex, Inc.
Target Recruit Count
36
Registration Number
NCT05487651
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

OHSU - Knight Cancer Center, Portland, Oregon, United States

🇺🇸

Baylor College of Medicine, Houston, Texas, United States

A PK Study of Oraxol in Breast Cancer Patients

Phase 1
Completed
Conditions
Breastcancer
Interventions
First Posted Date
2021-08-06
Last Posted Date
2021-08-06
Lead Sponsor
Athenex, Inc.
Target Recruit Count
24
Registration Number
NCT04993040
Locations
🇨🇳

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors

Phase 1
Withdrawn
Conditions
Advanced Solid Tumor
First Posted Date
2021-05-07
Last Posted Date
2022-09-02
Lead Sponsor
Athenex, Inc.
Registration Number
NCT04878484

A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients

Phase 2
Completed
Conditions
Solid Tumor
Interventions
First Posted Date
2019-11-27
Last Posted Date
2021-07-29
Lead Sponsor
Athenex, Inc.
Target Recruit Count
44
Registration Number
NCT04180384
Locations
🇦🇺

Monash Medical Centre, Clayton, Australia

🇳🇿

Auckland City Hospital, Auckland, New Zealand

🇳🇿

Dunedin Hospital, Dunedin, New Zealand

and more 5 locations

An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007

Phase 1
Terminated
Conditions
Breastcancer
Interventions
First Posted Date
2019-11-19
Last Posted Date
2022-03-03
Lead Sponsor
Athenex, Inc.
Target Recruit Count
11
Registration Number
NCT04168957
Locations
🇨🇳

Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan

🇨🇳

China Medical University Hospital, Taichung city, Taiwan

🇨🇳

Taipei Veterans Generla Hospital, Taipei, Taiwan, 11217, Taiwan

and more 2 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.